Abbott Laboratories Corporation

Abbvie Inc.

Genentech, Inc.

Walter and Eliza Hall Institute of Medical Research

Other

Andrew M Petros

Steven Elmore

Xilu Wang

Michael D Wendt

Milan Bruncko

Aaron R Kunzer

Hong Ding

William J McClellan

Xiaohong Song

Cheol-Min Park

Andrew J Souers

Christopher L Lynch

Le Wang

Zhi-Fu Tao

Lisa A Hasvold

Keith G Watson

John A Flygare

George A Doherty

Gary T Wang

Gerard M Sullivan

Stephen W Fesik

Chudi Obioma Ndubaku

Robert A Mantei

Jonathan Bayldon Baell

Wayne J Fairbrother

Laura A Hexamer

Danette Dudley

Thorsten K Oost

Wang Shen

David John Augeri

Saul H Rosenberg

Daniel A Dickman

Sheela A Thomas

Todd M Hansen

Yujia Dai

Noah Tu

Brad E Sleebs

Chinh Thien Bui

Guillaume Laurent Lessene

Alexander R Shoemaker

Brian John Smith

Chang H Park

Peter Colman

Peter Edward Czabotar

Michael J Mitten

George Nikolakopoulos

Jurgen Dinges

Philip J Hajduk

David G Nettesheim

Steven A Baumeister

Carl Steven Rye

Kurt Deshayes

Ho Sup Yoon

David D Nettesheim

Brad Edmund Sleebs

Danette A Dudley

Peter Malcom Colman

Thorsten Oost

Hosup Yoon

Steven W Elmore

William J Mcclellan

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Apoptosis promoters

In one aspect, the present invention provides for a compound of Formula I in which the variable X, X, X, X, Q, A, R, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Heterocyclic compounds and methods of use

N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.

N-acylsulfonamide apoptosis promoters

Growing community of inventors

Mundelein, IL, United States of America

Andrew M Petros